Drug Profile
Elarekibep - Pieris Pharmaceuticals
Alternative Names: AZD 1402; PRS-060; PRS-060/AZD1402Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Pieris Pharmaceuticals; University of Melbourne
- Developer AstraZeneca; Pieris Pharmaceuticals
- Class Antiasthmatics; Lipocalins
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 31 Dec 2023 Discontinued - Phase-I for Asthma (In volunteers) in Australia (IV)
- 31 Dec 2023 Discontinued - Phase-I for Asthma (In volunteers, In adults) in United Kingdom (Inhalation)
- 31 Dec 2023 Discontinued - Phase-I for Asthma (In volunteers, In adults) in United Kingdom (IV)